Apogee Therapeutics, Inc.
About Apogee Therapeutics, Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$255.8M
- Total assets
- $937.1M
- Market cap
- $6.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $285.6M
- Operating income
- -$285.6M
- Income tax
- $278.0K
- Net income
- -$255.8M
- EPS (basic)
- $-4.22
- EPS (diluted)
- $-4.22
Balance sheet
- Total assets
- $937.1M
- Current assets
- $741.4M
- Total liabilities
- $33.3M
- Current liabilities
- $27.9M
- Shareholders’ equity
- $903.9M
Cash flow
- Operating cash flow
- -$227.4M
- Investing cash flow
- -$179.6M
- Financing cash flow
- $396.5M
- Net cash flow
- -$10.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.6B
- EPS (diluted)
- $-4.22
- Shares outstanding
- 78.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 14, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $255.8M.
- Trading 10% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Apogee Therapeutics, Inc..
Write a review
News about Apogee Therapeutics, Inc.
News & sentiment via Polygon.io
